Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically Suppressed Patients
The FDA has approved Merck’s HIV two-drug regimen, IDVYNSO™ (doravirine/islatravir), the first and only non-integrase strand transfer inhibitor (non-INSTI), tenofovir-free, once-daily complete regimen for adults with virologically suppressed HIV-1 infection.
First Non-INSTI, Tenofovir-Free Option
This HIV two-drug regimen is indicated to replace current antiretroviral therapy in patients with HIV-1 RNA below 50 copies per mL who have no history of virologic treatment failure and no known resistance to doravirine. Phase 3 data showed non-inferior efficacy compared with the three-drug regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) while delivering a differentiated safety profile that meets the needs of aging patients managing multiple comorbidities.
The most impactful finding is the consistent non-inferior virologic efficacy of the HIV two-drug regimen versus established three-drug regimens in head-to-head Phase 3 switch studies. In the double-blind Trial 052, only 1% of participants switching to IDVYNSO experienced HIV-1 RNA ≥50 copies/mL at Week 48 — identical to those continuing BIC/FTC/TAF. In the open-label Trial 051, the HIV two-drug regimen demonstrated even greater suppression rates than baseline regimens. These results were consistent across age, sex, race, and prior treatment class.
Trial Design and Patient Demographics
The approval is supported by two randomized studies (Trial 052 and Trial 051) that enrolled 1,064 virologically suppressed adults. Participants had maintained HIV-1 RNA below 50 copies per mL for at least three months on stable therapy and had no documented treatment failure or doravirine resistance. The study populations closely mirrored real-world demographics, including 11% of IDVYNSO recipients aged 65 or older and substantial representation of Black/African American participants.
Economic and Clinical Advantages
By reducing pill burden and eliminating tenofovir exposure, the HIV two-drug regimen may lower long-term risks of bone, renal, and metabolic complications that drive healthcare costs. Minimal weight change and low discontinuation rates due to adverse events further support improved adherence and persistence. These attributes create a compelling value proposition for payers focused on lifetime antiretroviral costs and polypharmacy in an aging HIV population.
By offering the first non-INSTI, tenofovir-free two-drug regimen, IDVYNSO expands therapeutic choice and supports individualized, long-term HIV management.
